Lithuania · Medical and donor conditions

A clinical consultation desk with blank paperwork and a microscope visible through a glass partition; editorial illustration, not an actual clinic.

Lithuania: Medical and Donor Requirements in Surrogacy-Related Cases

Medical and donor questions in a surrogacy case must be separated into two tracks: whether a surrogacy arrangement is legally available in Lithuania, and what Lithuania requires for ordinary assisted reproduction using donor gametes. The distinction matters because donor-screening rules do not make a surrogacy arrangement lawful. This guide focuses on Lithuanian domestic law and ordinary assisted reproduction, not on recognition of a programme carried out abroad.

1. The legal boundary comes first

Article 11 of Lithuania’s Law on Assisted Reproduction states that civil transactions under which a woman undertakes to become pregnant, carry and give birth to a child, and then transfer the child to another person while relinquishing maternity rights, are null and void. The statutory test is the substance of the undertaking, not the label used by an agency. The clause does not distinguish altruistic from commercial arrangements.

Consequently, there is no basis to present Lithuanian donor or medical screening requirements as a route to approve a domestic surrogate. This is a civil-validity conclusion from Article 11; it should not be inflated into a claim about a separate criminal offence, a particular licensing penalty, or the treatment of every act associated with fertility care. Ordinary IVF and gamete donation remain separate questions governed by their own rules.

2. Medical grounds for ordinary assisted reproduction

For ordinary assisted reproduction, Article 5(1) identifies two categories of medical grounds: infertility cannot be cured by any treatment or there is no realistic chance of success; or treatment aims to prevent or treat a disease that causes severe disability, as defined by the health minister. These are statutory grounds, not merely a clinic’s preferred indication. Separately, Article 9 governs fertility-preservation services: a person’s current health, forecast health problems and/or planned treatment must create reasonable doubt about future fertility, confirmed by a medical council. That is a basis for fertility preservation, not a third Article 5 medical ground for ordinary assisted reproduction.

Treatment is prohibited when medical contraindications exist; the minister is responsible for approving the applicable list. Do not substitute a generic online list or an individual clinic’s webpage for that instrument. The Health Ministry’s published age of 42 applies to services funded by the Compulsory Health Insurance Fund, under stated conditions; that page alone does not establish a universal statutory maximum age for every privately funded procedure. Ask which rule and funding route the clinic is applying. The same page also describes funded treatment in terms of infertile partners. Because it predates the Constitutional Court ruling officially published in 2026, confirm how that wording is currently applied. The Ministry page was last updated on 3 December 2023, so confirm the current funding conditions before relying on the age limit.

Article 5(3) lists identity and age evidence, medical records proving the statutory indication, a written application and the prescribed informed-consent form. Its text also refers to marriage or registered-partnership documents. However, in its ruling of 10 April 2025, the Constitutional Court held that limiting access to married or registered-partnership persons was unconstitutional under Articles 29 and 53(1) of the Constitution. The Court postponed official publication until 10 April 2026; the ruling was officially published on that date, and the restriction cannot be applied to the extent declared unconstitutional. The separate medical-indication and contraindication requirements remain. Before proceeding, confirm whether legislation or provider forms have been updated since publication.

3. Documents and informed consent

Before treatment starts, the provider must explain methods and alternatives, benefits and risks, medical and psychological consequences, multiple-pregnancy risks, success rates for the proposed method and clinic, and storage periods for embryos not transferred. The information must also be provided in writing. The patient must receive the estimated total procedure price before signing. At least seven calendar days must pass between signature and the procedure start; consent can be withdrawn until fertilisation of the egg. Article 7’s current wording refers to both spouses/partners in the information and consent process. Following the 2026 ruling, a single applicant should ask the provider and Lithuanian counsel how this wording is applied; the ruling’s operative part addressed Article 5(3), so do not assume every consent-formality question is automatically resolved.

4. When donor gametes may be used

The Act prohibits commercial transactions in gametes and embryos. It nevertheless preserves a donor’s right to compensation for expenses incurred during gamete donation, with calculation and payment governed by the Government or its authorised institution; this is not a general authorisation for commercial sale. Article 3(7) permits assisted reproduction using a third-party donor’s gametes only in the stated circumstances, including where a spouse’s or partner’s gametes are damaged or insufficient, or their use carries a high risk of transmitting a minister-defined disease causing severe disability. Embryo donation is generally prohibited, with a narrow exception for a bank-stored embryo that the persons referred to in Article 5(3) have renounced in writing. Renunciation cannot occur until at least two years after assisted reproduction began, and ministerial procedures apply. Because this embryo-donation exception also cross-refers to Article 5(3), a single applicant should separately confirm with Lithuanian counsel how that reference applies after the 2026 ruling; the ruling’s operative part did not expressly resolve this question. A further unresolved point is that the Constitutional Court ruling officially published in 2026 concerned Article 5(3)’s marriage/registered-partnership restriction, while the current consolidated text of Article 3(7) still uses spouse/partner wording for donor-gamete use. The ruling does not expressly resolve how that condition applies to a single recipient. Do not assume that removing the family-status restriction automatically makes every donor-gamete route available; obtain a current written legal position from the provider or Lithuanian counsel. These rules concern ordinary assisted reproduction, not surrogacy.

5. Donor selection and health screening

For non-partner donation, the gamete bank must assess the donor’s age, medical and disease history and questionnaire, and conduct an interview through a designated, trained health professional. The rules also require attention to factors that could harm the donor, recipient or future child, including risks from egg retrieval, ovarian hyperstimulation, anaesthesia and psychological effects. The reviewed regulation refers to age as an assessment factor but does not establish a single universal numeric donor-age limit in the provisions checked here; a bank may have additional criteria.

For non-partner donors, the regulation requires blood testing for HIV-1/2 antibodies, hepatitis B surface antigen and core antibodies, hepatitis C antibodies and syphilis. Male gamete donors also undergo a urine test for chlamydia using a nucleic-acid amplification method. HTLV-1 testing applies in specified high-prevalence or exposure circumstances. Further tests, for example for malaria or cytomegalovirus, may be selected based on health history, travel and the cells’ characteristics. Screening reduces risk; it does not guarantee that every risk has been eliminated.

Partner donation follows a different testing framework. In direct-use partner donation, infection tests may be optional under the regulation; positive results do not automatically bar direct use. For indirect use, testing and handling requirements apply, and positive or missing HIV/HBV/HCV results or a known infection risk can require separate storage. Do not copy the non-partner donor’s positive-test exclusion mechanically onto partner donation: the applicable route and safeguards matter.

With the donor’s consent, the bank carries out genetic screening for autosomal-recessive genes prevalent in the donor’s ethnic background and assesses transmission risk for hereditary diseases in the family. If the donor declines these tests, the recipient must be told about the associated risk and the measures used to reduce it. The text therefore does not support saying that this particular genetic screening is invariably compulsory for every donor; consent and risk disclosure are material.

Non-partner donor gametes are subject to a minimum 180-day quarantine followed by repeat testing under the prescribed protocol. The regulation permits limited alternatives: additional nucleic-acid testing for HIV, hepatitis B and hepatitis C may remove the need for repeat blood testing, or a validated pathogen-removal processing step may remove the retesting requirement for the relevant viruses. The clinic or bank should identify in writing which route it uses and the supporting protocol. An initial negative test alone does not make quarantine optional.

6. Exclusions, bank criteria and donor limits

Gametes or tissues must not be collected or used where the donor’s health creates a significant risk to the donor or recipient, or a risk of severe disability to a child, unless an appropriate health technology can avoid that risk. The same principle applies where improper collection, processing, storage or distribution creates a serious risk. The regulation also bars gametes from specified genetically related pairings, including parent–child, siblings, grandparent–grandchild, first cousins and certain aunt/uncle–niece/nephew relationships. For non-partner donation, positive results for the specified infection tests are an exclusion.

The bank may set additional exclusion conditions, so its policy can be stricter than the minimum rules. This does not mean every internal preference is a statutory requirement: ask the bank to identify the legal clause and separately label its own policy. Once gametes from one donor have resulted in five live-born children, that donor’s gametes may no longer be used. Ask how the bank tracks this limit and confirms availability before relying on a donor.

7. Confidentiality is not an absolute anonymity promise

Donor and recipient data are confidential, but it is unsafe to promise absolute, permanent anonymity. Under Article 3(10), a court may authorise disclosure where needed for health or other important reasons; identity may also be provided to a person born through donor gametes when that person reaches adulthood or full legal capacity if the donor has consented. Order V-647 sets out an administrative procedure for requests. A donor agreement should explain this framework rather than guarantee that identity can never be disclosed.

8. What to ask before proceeding

Separate binding law from clinic policy in every quote or checklist. Binding rules include statutory medical grounds, the contraindication framework, consent and timing, gamete/embryo transaction restrictions, donor testing, quarantine and the five-child limit. A clinic’s protocol may determine appointment sequencing, additional tests it recommends, how it applies lawful additional bank criteria and which records it requests; it cannot legalise a void surrogacy transaction. A clinic website is evidence of its stated practice, not proof that a requirement appears in legislation. Ask for the actual licence scope of the facility and bank; general registration as a healthcare provider is not, by itself, proof that the specific assisted-reproduction or gamete-bank service is licensed.

Before paying or starting treatment, ask the licensed provider or gamete bank for: (1) the exact legal basis for the proposed procedure and confirmation that it is not a surrogacy arrangement; (2) the current minister-approved contraindication list and written clinical indication; (3) the donor-screening panel, genetic-screening consent form, quarantine/retesting route and any bank-specific exclusions; (4) written informed consent, the estimated total price and embryo-storage terms; and (5) the current legal basis for recipient eligibility, taking account of the Constitutional Court annotation. Keep copies of forms, lab results and the bank’s explanation. Recheck the official register before relying on any rule after 21 October 2026. If the applicant has no spouse or registered partner, ask specifically how Articles 3(7) and 7 are applied after the ruling.

Official sources

The linked legal and government materials are in Lithuanian. The source check for this guide was performed on 21 October 2026. The official register’s indexed edition list shows the donor-bank regulation consolidated from 10 March 2023, with Order V-315 as the latest listed amendment; direct page retrieval was restricted in this check. The Ministry page on funding was last updated on 3 December 2023; verify current funding conditions and the minister-approved contraindication list.

Last updated:

Author: Khachatrian Razmik, LL.M.

International surrogacy and parentage legal services — LEX SURROGACY by Lex Agency · Author profile · Editorial standards